An unmet need: Harmonization of IL-7 and IL-15 combination for the ex vivo generation of minimally differentiated T cells.
Fiche publication
Date publication
février 2021
Journal
Cellular immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GODET Yann, Dr GALAINE Jeanne
Tous les auteurs :
Marton C, Mercier-Letondal P, Galaine J, Godet Y
Lien Pubmed
Résumé
T cell-based adoptive cell transfer therapy is now clinically used to fight cancer with CD19-targeting chimeric antigen receptor T cells. The use of other T cell-based immunotherapies relying on antigen-specific T cells, genetically modified or not, is expanding in various neoplastic diseases. T cell manufacturing has evolved through sophisticated processes to produce T cells with improved therapeutic potential. Clinical-grade manufacturing processes associated with these therapies must meet pharmaceutical requirements and therefore be standardized. Here, we focus on the use of cytokines to expand minimally differentiated T cells, as well as their standardization and harmonization in research and clinical settings.
Mots clés
Adoptive cell transfer, Interleukin-15, Interleukin-7, Standardization, T cell differentiation
Référence
Cell Immunol. 2021 Feb 23;363:104314